Dyne Therapeutics (DYN) News Today → “This will be one of the biggest revolutions ever.” - NVIDIA CEO (From Behind the Markets) (Ad) Free DYN Stock Alerts $31.88 +0.68 (+2.18%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 8:26 AM | americanbankingnews.comChardan Capital Weighs in on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN)May 31 at 8:25 AM | marketbeat.comFY2024 Earnings Estimate for Dyne Therapeutics, Inc. Issued By Chardan Capital (NASDAQ:DYN)Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Analysts at Chardan Capital increased their FY2024 earnings per share estimates for Dyne Therapeutics in a research report issued on Tuesday, May 28th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per shareMay 30 at 7:30 AM | globenewswire.comDyne Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesMay 24, 2024 | americanbankingnews.comDyne Therapeutics, Inc. (NASDAQ:DYN) Insider Oxana Beskrovnaya Sells 30,426 SharesMay 23, 2024 | bizjournals.comThe Petri Dish: Dyne’s public offering, Kronos’ new CFOMay 23, 2024 | insidertrades.comInsider Selling: Dyne Therapeutics, Inc. (NASDAQ:DYN) Insider Sells 30,426 Shares of StockMay 23, 2024 | americanbankingnews.comDyne Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.41) Per Share (NASDAQ:DYN)May 22, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $32.63Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $32.63May 22, 2024 | forbes.comUp 165% This Year Will Dyne Therapeutics Continue Its Stellar Run?May 22, 2024 | marketbeat.comFY2025 EPS Estimates for Dyne Therapeutics, Inc. (NASDAQ:DYN) Lifted by HC WainwrightDyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - HC Wainwright increased their FY2025 earnings per share (EPS) estimates for Dyne Therapeutics in a research report issued to clients and investors on Monday, May 20th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.41)May 22, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) PT Raised to $42.00 at Chardan CapitalMay 22, 2024 | markets.businessinsider.comDyne Therapeutics Prices Public Offering Of 10.50 Mln Shares At $31.00/shrMay 22, 2024 | americanbankingnews.comDyne Therapeutics (NASDAQ:DYN) Hits New 52-Week High Following Analyst UpgradeMay 21, 2024 | globenewswire.comDyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common StockMay 21, 2024 | seekingalpha.comDyne Therapeutics: Progress Undenied In DM1 And DMD TrialsMay 21, 2024 | finance.yahoo.comAnnouncement of The Shaw Laureates 2024May 21, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month High on Analyst UpgradeDyne Therapeutics (NASDAQ:DYN) Reaches New 12-Month High Following Analyst UpgradeMay 21, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Given New $42.00 Price Target at Chardan CapitalChardan Capital upped their target price on shares of Dyne Therapeutics from $31.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday.May 20, 2024 | msn.comWhy Is Dyne Therapeutics Stock Soaring On Monday?May 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dyne Therapeutics (DYN)May 20, 2024 | finance.yahoo.comWhy Dyne Therapeutics, With A 166% Run This Year, Just Catapulted AgainMay 20, 2024 | globenewswire.comDyne Therapeutics Announces Proposed Public Offering of Common StockMay 20, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Price Target Raised to $42.00 at Jefferies Financial GroupJefferies Financial Group boosted their price target on shares of Dyne Therapeutics from $36.00 to $42.00 and gave the company a "buy" rating in a research note on Monday.May 20, 2024 | marketwatch.comDyne Therapeutics Shares Rise 23% on Favorable Drug DataMay 20, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Up After Analyst UpgradeDyne Therapeutics (NASDAQ:DYN) Shares Gap Up Following Analyst UpgradeMay 20, 2024 | investors.comWhy Dyne Therapeutics, With A 108% Run This Year, Just Catapulted AgainMay 20, 2024 | msn.comPTC Therapeutics, Oragenics, GT Biopharma among healthcare moversMay 20, 2024 | za.investing.comDyne Therapeutics Inc. stock jumps following trial updatesMay 20, 2024 | msn.comDyne Therapeutics announces data from early stage trials of muscular dystrophy treatmentsMay 20, 2024 | marketwatch.comDyne Therapeutics Discloses Positive Trial Data for DYNE-101, DYNE-251 TreatmentsMay 20, 2024 | markets.businessinsider.comDyne Therapeutics Reports Positive Data From Phase 1/2 ACHIEVE And Phase 1/2 DELIVER StudiesMay 20, 2024 | globenewswire.comDyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional EndpointsMay 19, 2024 | globenewswire.comDyne Therapeutics to Host Virtual Investor Event to Review New Clinical Data from the ACHIEVE and DELIVER Trials Tomorrow, May 20 at 8:00 a.m. ETMay 19, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from AnalystsDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has earned a consensus recommendation of "Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to theMay 18, 2024 | insidertrades.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Richard William Scalzo Sells 2,588 SharesMay 18, 2024 | marketbeat.comRussell Investments Group Ltd. Reduces Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Russell Investments Group Ltd. reduced its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 31.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 100,496 shares of the company's stock after selling 46,650 shares durMay 17, 2024 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) SVP Sells $73,162.76 in StockDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) SVP Richard William Scalzo sold 2,588 shares of the firm's stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $28.27, for a total transaction of $73,162.76. Following the completion of the transaction, the senior vice president now owns 116,695 shares in the company, valued at approximately $3,298,967.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.May 17, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 3.2%Dyne Therapeutics (NASDAQ:DYN) Trading Down 3.2%May 16, 2024 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $29.38Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down to $29.38May 8, 2024 | marketbeat.comDyne Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($2.94) Per Share (NASDAQ:DYN)Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Dyne Therapeutics in a report released on Monday, May 6th. Chardan Capital analyst K. Nakae forecasts that the company will post earningsMay 6, 2024 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Aldeyra Therapeutics (ALDX)May 6, 2024 | marketbeat.comDyne Therapeutics' (DYN) Outperform Rating Reaffirmed at OppenheimerOppenheimer reissued an "outperform" rating and issued a $47.00 target price on shares of Dyne Therapeutics in a report on Monday.May 6, 2024 | markets.businessinsider.comRobust Financial Health and Promising Clinical Trials Bolster Buy Rating for Dyne TherapeuticsMay 4, 2024 | finance.yahoo.comWe're Hopeful That Dyne Therapeutics (NASDAQ:DYN) Will Use Its Cash WiselyMay 4, 2024 | finance.yahoo.comDyne Therapeutics Inc (DYN) Q1 2024 Earnings: Aligns with Analyst ProjectionsMay 3, 2024 | finanznachrichten.deDyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 3, 2024 | msn.comDYN Stock Earnings: Dyne Therapeutics Misses EPS for Q1 2024May 2, 2024 | finance.yahoo.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 2, 2024 | globenewswire.comDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. DYN Media Mentions By Week DYN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.950.78▲Average Medical News Sentiment DYN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼74▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Amphastar Pharmaceuticals News Today Protagonist Therapeutics News Today Calliditas Therapeutics AB (publ) News Today Esperion Therapeutics News Today Catalent News Today Roivant Sciences News Today Elanco Animal Health News Today Ascendis Pharma A/S News Today Legend Biotech News Today Cerevel Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
